Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment
Related news for (MDNAF)
- Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
- Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
- Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
- Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
- Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe